US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the first 100 patients using its Tomo C Radiation Treatment Delivery System at the Shandong Cancer Hospital and Institute. The milestone marks a significant achievement for the Tomo C System, which was developed through the CNNC-Accuray joint venture and is manufactured in China.
Tomo C System: Features and Impact
The Tomo C System, registered in China in 2019, was installed at the Shandong Cancer Hospital and Institute in July of last year. The system is a high-end radiotherapy solution that combines high-definition imaging, rapid treatment delivery, and precise adaptive capabilities. It pioneers an integrated precision radiotherapy approach by merging spiral CT imaging with spiral tomography radiotherapy. This seamless integration of diagnosis and treatment processes significantly reduces treatment time and enhances patient outcomes.
Market and Clinical Implications
The completion of the first 100 patient treatments with the Tomo C System underscores its clinical effectiveness and acceptance in the Chinese market. As a leading-edge technology, the Tomo C System addresses the growing demand for advanced radiotherapy solutions in oncology. Accuray’s collaboration with CNNC highlights the company’s commitment to expanding its footprint in China and delivering innovative cancer treatment options to patients.-Fineline Info & Tech
Leave a Reply